From the bench to the bedside: ways to improve rituximab efficacy.

Rituximab (MabThera, Rituxan) is a chimeric IgG1 monoclonal antibody that specifically targets the CD20 surface antigen expressed on normal and neoplastic B-lymphoid cells. Rituximab is currently used in the treatment of both follicular and aggressive B-cell non-Hodgkin lymphomas. Despite its demonstrated clinical effectiveness, its in vivo mechanisms of action remain unknown and could differ by subtype of lymphoma. Rituximab has been shown to induce apoptosis, complement-mediated lysis, and antibody-dependent cellular cytotoxicity in vitro, and some evidence points toward an involvement of these mechanisms in vivo. Rituximab also has a delayed therapeutic effect as well as a potential "vaccinal" effect. Here, we review the current understanding of the mechanism of action of rituximab and discuss approaches that could increase its clinical activity. A better understanding of how rituximab acts in vivo should make it possible to develop new and more effective therapeutic strategies.

[1]  J. Jaffrezou,et al.  Rituximab antiproliferative effect in B-lymphoma cells is associated with acid-sphingomyelinase activation in raft microdomains. , 2004, Blood.

[2]  M. Cragg,et al.  Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. , 2004, Blood.

[3]  J. Byrd,et al.  FcγRIIIa and FcγRIIa polymorphisms do not predict response to rituximab in B-cell chronic lymphocytic leukemia , 2004 .

[4]  U. Jäger,et al.  Cross-Priming of Cytotoxic T Cells Promoted by Apoptosis-Inducing Tumor Cell Reactive Antibodies? , 2002, Journal of Clinical Immunology.

[5]  M. Czuczman,et al.  Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  W. Weng,et al.  Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. Lytton,et al.  Store-operated Cation Entry Mediated by CD20 in Membrane Rafts* , 2003, Journal of Biological Chemistry.

[8]  M. Cragg,et al.  CD20-induced lymphoma cell death is independent of both caspases and its redistribution into triton X-100 insoluble membrane rafts. , 2003, Cancer research.

[9]  A. Nagler,et al.  Rituximab reduces relapse risk after allogeneic and autologous stem cell transplantation in patients with high‐risk aggressive non‐Hodgkin's lymphoma , 2003, British journal of haematology.

[10]  Valeria Grieco,et al.  Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo 1 , 2003, The Journal of Immunology.

[11]  P. Gaulard,et al.  Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). , 2003, Blood.

[12]  Judy Lieberman,et al.  Cell death and immunity: The ABCs of granule-mediated cytotoxicity: new weapons in the arsenal , 2003, Nature Reviews Immunology.

[13]  Y. Vugmeyster,et al.  Effect of anti‐CD20 monoclonal antibody, Rituxan, on cynomolgus monkey and human B cells in a whole blood matrix , 2003, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[14]  K. Do,et al.  Circulating CD20 is detectable in the plasma of patients with chronic lymphocytic leukemia and is of prognostic significance. , 2003, Blood.

[15]  R. Gressin,et al.  In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. , 2003, Blood.

[16]  I. Sanz,et al.  The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus , 2003 .

[17]  G. Trinchieri,et al.  Interleukin-12 and the regulation of innate resistance and adaptive immunity , 2003, Nature Reviews Immunology.

[18]  M. Cragg,et al.  Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. , 2003, Blood.

[19]  K. Shitara,et al.  The Absence of Fucose but Not the Presence of Galactose or Bisecting N-Acetylglucosamine of Human IgG1 Complex-type Oligosaccharides Shows the Critical Role of Enhancing Antibody-dependent Cellular Cytotoxicity* , 2003, The Journal of Biological Chemistry.

[20]  D. Hoessli,et al.  Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. , 2003, Cancer research.

[21]  I. Sanz,et al.  The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. , 2003, Arthritis and rheumatism.

[22]  J. Hainsworth,et al.  Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Polyak,et al.  CD20‐mediated apoptosis: signalling through lipid rafts , 2002, Immunology.

[24]  D. Maloney,et al.  Glucocorticoids and rituximab in vitro: synergistic direct antiproliferative and apoptotic effects. , 2002, Blood.

[25]  S. Lederman,et al.  CD20-induced B cell death can bypass mitochondria and caspase activation , 2002, Leukemia.

[26]  K. Rafiq,et al.  Immune complex-mediated antigen presentation induces tumor immunity. , 2002, The Journal of clinical investigation.

[27]  J. Ravetch,et al.  Inducing Tumor Immunity through the Selective Engagement of Activating Fcγ Receptors on Dendritic Cells , 2002, The Journal of experimental medicine.

[28]  M. Polyak,et al.  Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure. , 2002, Blood.

[29]  B. Bonavida,et al.  Rituximab modifies the cisplatin-mitochondrial signaling pathway, resulting in apoptosis in cisplatin-resistant non-Hodgkin's lymphoma. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[30]  J. Byrd,et al.  The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. , 2002, Blood.

[31]  G. Salles,et al.  Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. , 2002, Blood.

[32]  T. Habermann,et al.  Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma. , 2002, Blood.

[33]  T. Barbui,et al.  CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. , 2001, Blood.

[34]  J. Baars,et al.  Complement activation plays a key role in the side‐effects of rituximab treatment , 2001, British journal of haematology.

[35]  A. López-Guillermo,et al.  Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. , 2001, Blood.

[36]  E. Erba,et al.  Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone , 2001, British journal of haematology.

[37]  W. Weng,et al.  Expression of complement inhibitors CD46, CD55, and CD59 on tumor cells does not predict clinical outcome after rituximab treatment in follicular non-Hodgkin lymphoma. , 2001, Blood.

[38]  J. Davies,et al.  Expression of GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of antibodies with altered glycoforms leads to an increase in ADCC through higher affinity for FC gamma RIII. , 2001, Biotechnology and bioengineering.

[39]  O. Press,et al.  Synergistic effects of the fenretinide (4-HPR) and anti-CD20 monoclonal antibodies on apoptosis induction of malignant human B cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  B. Bonavida,et al.  Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. , 2001, Cancer research.

[41]  N. Mitsiades,et al.  Tumor Cell Expression of CD59 Is Associated With Resistance to CD20 Serotherapy in Patients With B-Cell Malignancies , 2001, Journal of immunotherapy.

[42]  Leonard G. Presta,et al.  High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR* , 2001, The Journal of Biological Chemistry.

[43]  E. Vitetta,et al.  Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. , 2001, Blood.

[44]  B. Bonavida,et al.  Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  L. Presta,et al.  Engineered Antibodies with Increased Activity to Recruit Complement , 2001, The Journal of Immunology.

[46]  J. Edwards,et al.  Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. , 2001, Rheumatology.

[47]  S. Sacchi,et al.  Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and Rituximab in patients with relapsed low grade non-Hodgkin's lymphoma. , 2001, Haematologica.

[48]  L. Presta,et al.  FcRn and Design of IgG 1 Variants with Improved Binding to the Fc g R * , 2001 .

[49]  B. Dörken,et al.  Anti-CD20- and B-cell receptor-mediated apoptosis: evidence for shared intracellular signaling pathways. , 2000, Cancer research.

[50]  M. Czuczman,et al.  Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  T. Sauerbruch,et al.  Mechanism of cytotoxicity induced by chimeric mouse human monoclonal antibody IDEC-C2B8 in CD20-expressing lymphoma cell lines. , 2000, Cellular immunology.

[52]  D. Maloney,et al.  Combination immunotherapy of relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma with rituximab and interferon-alpha-2a. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[53]  S. Bernasconi,et al.  Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. , 2000, Blood.

[54]  Meri,et al.  Rituximab (Anti‐CD20) Therapy of B‐Cell Lymphomas: Direct Complement Killing is Superior to Cellular Effector Mechanisms , 2000, Scandinavian journal of immunology.

[55]  P. Venugopal,et al.  Effects of cytokines on CD20 antigen expression on tumor cells from patients with chronic lymphocytic leukemia. , 2000, Leukemia research.

[56]  Leonard G. Presta,et al.  Mapping of the C1q Binding Site on Rituxan, a Chimeric Antibody with a Human IgG1 Fc , 2000, The Journal of Immunology.

[57]  J. K. Hofmeister,et al.  Clustered CD20 induced apoptosis: src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis. , 2000, Blood cells, molecules & diseases.

[58]  L. Presta,et al.  Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.

[59]  J. Ledbetter,et al.  Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells , 2000, Cancer Immunology, Immunotherapy.

[60]  V. Diehl,et al.  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8) , 2016 .

[61]  L. Koh,et al.  Re-evaluation of benefits of BRCA1/2 testing. , 1999 .

[62]  L. Koh,et al.  Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  James E. Bailey,et al.  Engineered glycoforms of an antineuroblastoma IgG1 with optimized antibody-dependent cellular cytotoxic activity , 1999, Nature Biotechnology.

[64]  R. Al-Daccak,et al.  CD20 is physically and functionally coupled to MHC class II and CD40 on human B cell lines , 1999, European journal of immunology.

[65]  L. Vasovic,et al.  Cellular requirements for the monoclonal antibody‐mediated eradication of an established solid tumor , 1999, European journal of immunology.

[66]  M. Polyak,et al.  Identification of a cytoplasmic region of CD20 required for its redistribution to a detergent-insoluble membrane compartment. , 1998, Journal of immunology.

[67]  M. Czuczman,et al.  Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[68]  D. Rubinstein,et al.  Immune reconstitution and immunotherapy after autologous hematopoietic stem cell transplantation. , 1998, Blood.

[69]  R. Levy,et al.  Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[70]  M. Neuberger,et al.  Mice carrying a CD20 gene disruption , 1998, Immunogenetics.

[71]  J. Ledbetter,et al.  Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. , 1998, Blood.

[72]  I. T. Ten Berge,et al.  Administration of OKT3 as a two-hour infusion attenuates first-dose side effects. , 1997, Transplantation.

[73]  B. Lucas,et al.  PU.1/Pip and basic helix loop helix zipper transcription factors interact with binding sites in the CD20 promoter to help confer lineage- and stage-specific expression of CD20 in B lymphocytes. , 1997, Blood.

[74]  D. Maloney,et al.  IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  D. Roos,et al.  FcγRIIIa-158V/F Polymorphism Influences the Binding of IgG by Natural Killer Cell FcγRIIIa, Independently of the FcγRIIIa-48L/R/H Phenotype , 1997 .

[76]  D. R. Anderson,et al.  Targeted anti-cancer therapy using rituximab, a chimaeric anti-CD20 antibody (IDEC-C2B8) in the treatment of non-Hodgkin's B-cell lymphoma. , 1997, Biochemical Society transactions.

[77]  D. Roos,et al.  Fc gammaRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. , 1997, Blood.

[78]  S L Morrison,et al.  Effect of glycosylation on antibody function: implications for genetic engineering. , 1997, Trends in biotechnology.

[79]  D. Longo,et al.  Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas. , 1996, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[80]  G. Schieven,et al.  Association of 75/80-kDa Phosphoproteins and the Tyrosine Kinases Lyn, Fyn, and Lck with the B Cell Molecule CD20 , 1995, The Journal of Biological Chemistry.

[81]  L. Genestier,et al.  Tumor necrosis factor-α up-regulates Bcl-2 expression and decreases calcium-dependent apoptosis in human B cell lines , 1995 .

[82]  L. Genestier,et al.  Tumor necrosis factor-alpha up-regulates Bcl-2 expression and decreases calcium-dependent apoptosis in human B cell lines. , 1995, International immunology.

[83]  W. Di Berardino,et al.  CD20 monoclonal antibodies stimulate extracellular cleavage of the low affinity receptor for IgE (Fc epsilon RII/CD23) in Epstein-Barr-transformed B cells. , 1994, The Journal of biological chemistry.

[84]  P. Chinn,et al.  Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. , 1994, Blood.

[85]  M. Klemsz,et al.  Hematopoietic lineage- and stage-restricted expression of the ETS oncogene family member PU.1. , 1993, Blood.

[86]  G. Schieven,et al.  Association of tyrosine and serine kinases with the B cell surface antigen CD20. Induction via CD20 of tyrosine phosphorylation and activation of phospholipase C-gamma 1 and PLC phospholipase C-gamma 2. , 1993, Journal of immunology.

[87]  Z. Oltvai,et al.  Bcl-2 functions in an antioxidant pathway to prevent apoptosis , 1993, Cell.

[88]  R. Frizzell,et al.  Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes , 1993, The Journal of cell biology.

[89]  B. Lucas,et al.  Cell type- and stage-specific expression of the CD20/B1 antigen correlates with the activity of a diverged octamer DNA motif present in its promoter. , 1993, The Journal of biological chemistry.

[90]  I. Bourget,et al.  CD20 monoclonal antibodies down‐regulate IgM at the surface of B cells , 1993, European journal of immunology.

[91]  John Calvin Reed,et al.  Apoptosis induced by withdrawal of interleukin-3 (IL-3) from an IL-3-dependent hematopoietic cell line is associated with repartitioning of intracellular calcium and is blocked by enforced Bcl-2 oncoprotein production. , 1993, The Journal of biological chemistry.

[92]  J. Giorgi,et al.  CD20 (pan-B cell) antigen is expressed at a low level on a subpopulation of human T lymphocytes. , 1993, Cytometry.

[93]  M. Valentine,et al.  Rescue from anti‐IgM‐induced programmed cell death by the B cell surface proteins CD20 and CD40 , 1992, European journal of immunology.

[94]  D. Morris,et al.  Activation of dense human tonsilar B cells. Induction of c-myc gene expression via two distinct signal transduction pathways. , 1991, Journal of immunology.

[95]  P. Sperryn,et al.  Blood. , 1989, British journal of sports medicine.

[96]  T. Whiteside,et al.  Recombinant human granulocyte/macrophage colony-stimulating factor enhances monocyte cytotoxicity and secretion of tumor necrosis factor alpha and interferon in cancer patients. , 1989, Blood.

[97]  J. Brown,et al.  Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. , 1988, The EMBO journal.

[98]  E. Smeland,et al.  Activation of human B cells: alternate options for initial triggering and effects of nonmitogenic concentrations of anti-IgM antibodies on resting and activated cells. , 1987, Journal of immunology.

[99]  F. Appelbaum,et al.  Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas. , 1987, Blood.

[100]  L. Lanier,et al.  Dissection of the lymphokine-activated killer phenomenon. Relative contribution of peripheral blood natural killer cells and T lymphocytes to cytolysis , 1986, The Journal of experimental medicine.

[101]  E. Clark,et al.  The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. , 1985, Journal of immunology.

[102]  E. Clark,et al.  Role of the Bp35 cell surface polypeptide in human B-cell activation. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[103]  S. Pestka,et al.  Effect of human recombinant interferon on cytotoxic activity of natural killer (NK) cells and monocytes. , 1982, Cellular immunology.